- Home
- DCTH vs ATXS Comparison
DCTH vs ATXS Comparison
Compare DCTH & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- ATXS
- Stock Information
- Founded
- DCTH 1988
- ATXS 2008
- Country
- DCTH United States
- ATXS United States
- Employees
- DCTH N/A
- ATXS N/A
- Industry
- DCTH Medical/Dental Instruments
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- DCTH Health Care
- ATXS Health Care
- Exchange
- DCTH Nasdaq
- ATXS Nasdaq
- Market Cap
- DCTH 388.3M
- ATXS 424.4M
- IPO Year
- DCTH N/A
- ATXS 2015
- Fundamental
- Price
- DCTH $10.67
- ATXS $7.37
- Analyst Decision
- DCTH Strong Buy
- ATXS Buy
- Analyst Count
- DCTH 4
- ATXS 6
- Target Price
- DCTH $24.50
- ATXS $32.00
- AVG Volume (30 Days)
- DCTH 485.5K
- ATXS 315.6K
- Earning Date
- DCTH 11-07-2025
- ATXS 11-12-2025
- Dividend Yield
- DCTH N/A
- ATXS N/A
- EPS Growth
- DCTH N/A
- ATXS N/A
- EPS
- DCTH 0.06
- ATXS N/A
- Revenue
- DCTH $70,240,000.00
- ATXS N/A
- Revenue This Year
- DCTH $159.22
- ATXS N/A
- Revenue Next Year
- DCTH $41.22
- ATXS N/A
- P/E Ratio
- DCTH $193.75
- ATXS N/A
- Revenue Growth
- DCTH 491.35
- ATXS N/A
- 52 Week Low
- DCTH $8.08
- ATXS $3.56
- 52 Week High
- DCTH $18.23
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- DCTH 43.30
- ATXS 57.31
- Support Level
- DCTH $10.60
- ATXS $7.12
- Resistance Level
- DCTH $11.38
- ATXS $7.94
- Average True Range (ATR)
- DCTH 0.44
- ATXS 0.48
- MACD
- DCTH 0.01
- ATXS 0.06
- Stochastic Oscillator
- DCTH 5.26
- ATXS 69.38
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.